• Meet the diagnostic criteria of MOH in ICHD-3;

• A history of migraine (according to ICHD-3 criteria)/tension headache (TTH) (according to ICHD-3 criteria) for ≥12 months before screening;

• Patients entered data from the electronic headache diary for at least 24 of the 28 days of the screening period (evidence of good adherence to the electronic headache diary);

• Prospectively collected data from the electronic headache diary during the screening period met the following criteria: 15 or more headache days per month; Regular overdose of acute or symptomatic headache medications meets the diagnostic criteria for MOH；

• Headache diagnosed before the age of 50 years;

• Patients had failed MOH withdrawal treatment (with medical documentation or specific physician confirmation of each treatment) on ≥1 occasions in the previous 3 years; Withdrawal treatment failure is defined as no significant reduction in headache frequency, duration and/or severity after withdrawal treatment; Or intolerable withdrawal reactions during withdrawal treatment; Or unable to quit treatment due to safety issues;

• Aged between 18 and 80 years old;

• Signed the informed consent and volunteered to participate in the study.

• Patients who met the above 8 criteria were included in this study.

• According to the ICHD-3 criteria, it met the diagnostic criteria of episodic migraine; With/without tension-type headache;

• Headache days/month ≤6 days at enrollment;

• The number of days/month of using analgesics at enrollment was ≤6 days;

• Age between 18 and 80 years;

• Be able to fill out a headache diary;

• No previous history of drug abuse;

• No obvious comorbidities pain, physical or mental disorders;

• No alcohol or drug addiction;

• No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months;

• No headache or headache ≤2 days in the past 12 months at enrollment;

• No more than 6 days/month of use of analgesics at enrollment;

• Age between 18 and 80 years;

• No significant comorbidities pain, physical, or mental disorders;

• No organic, functional changes or systemic diseases that could cause headache;

• No history of head or neck trauma;

• No significant abnormalities in blood routine, biochemical tests, coagulation function, or urine routine in the past 12 months prior to enrollment;

• No alcohol or drug addiction;

• No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months.

⁃ Nonrandomized patients with MOH:

⁃ ●Participants who meet the MOH diagnostic criteria and fulfill the inclusion/exclusion criteria but decline randomization will be assigned to the non-randomized electroacupuncture group. These participants will receive electroacupuncture treatment directly, with no restrictions on the number of participants per center.